STAT3 inhibitor DSP-0337
Term · Oncology and biomedicine · MLC-T-ONC-016869
An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.
| Identifier | MLC-T-ONC-016869 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | napabucasin prodrug DSP-0337; cancer stemness inhibitor DSP-0337 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016869",
"term": "STAT3 inhibitor DSP-0337",
"field": "Oncology and biomedicine",
"definition": "An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.",
"synonyms": [
"napabucasin prodrug DSP-0337",
"cancer stemness inhibitor DSP-0337"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/stat3-inhibitor-dsp-0337/"
}
Record 15,635 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.